newsfilter
← Latest News
GlobeNewswire·

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance